Stock 1672 ASCLETIS PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Ascletis Pharma Inc.

Equities

1672

KYG0520K1094

Delayed Hong Kong S.E.
Other stock markets
 11:17:10 2024-07-02 pm EDT 		5-day change 1st Jan Change
0.93 HKD +1.09% Intraday chart for Ascletis Pharma Inc. +9.41% -36.30%
Jul. 02 Hong Kong Stocks Gain Following Encouraging Chinese Manufacturing Data MT
Jul. 02 Ascletis Pharma Board Approves Up to HK$200 Million Share Buyback Plan; Shares Surge 13% MT

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Hong Kong Stocks Gain Following Encouraging Chinese Manufacturing Data
MT
Ascletis Pharma Board Approves Up to HK$200 Million Share Buyback Plan; Shares Surge 13%
MT
Ascletis Pharma : Gannex Announces Poster Presentation Describing Positive Interim 12 Week Results from Ongoing 52 Week Phase II Clinical Trial of Once Daily ASC41 in Patients with Biopsy Confirmed MASH at EASL CONGRESS 2024
PU
Gannex Announces Poster Presentation of Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024
PR
Ascletis Pharma Inc. Announces Presentation Designing Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy- Confirmed Mash At EASL Congress 2024
CI
Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus
MT
Ascletis Announces Strategic Decisions on FXR agonist ASC42
PR
Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42
CI
Ascletis Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Ascletis Pharma Inc. Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting
CI
Ascletis Pharma Doses First Patient in Phase 3 Clinical Trial of Acne Vulgaris Drug
MT
Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
PR
Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase III Clinical Trial of Asc40 (Denifanstat) for Treatment of Acne
CI
Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
PR
Ascletis Pharma's Liver Treatment Reduces Fat in 9 of 10 Participants During Phase 2 Trial
MT
Ascletis Pharma Inc. Announces Positive Interim Results from 52-Week Phase Ii Clinical Trial of Once-Daily Asc41 Tablet in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis
CI
Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis
PR
Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 for Treatment of Acne
AQ
Ascletis Pharma Gets Nod to Trial Acne Drug
MT
Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1672 Stock
  4. News Ascletis Pharma Inc.